

[gw22-e0892]

**THE ANALYSIS OF 60 PATIENTS OF ESSENTIAL HYPERTENSION TREATMENT WITH METOPROLOL SUCCINATE SUSTAINED-RELEASE TABLETS**Zhang Feng, Ranping *Department of Cardiology, Municipal Hospital Ward Cadres*

10.1136/heartjnl-2011-300867.592

**Objective** To observe the effects of metoprolol succinate sustained-release tablets in treating mild to moderate essential hypertension.

**Methods** Sixty adults with mild and moderate essential hypertension were randomly divided into two groups of 30 patients: the treatment group metoprolol succinate sustained-release tablets oral 47.5 mg once a day, one time follow-up a week. Two weeks if no change to ineffective use of metoprolol succinate sustained-release tablets, 95 mg was given orally once a day, 4 weeks a course of treatment; the control group, amlodipine besylate tablets 2.5–5 mg once a day, one time follow-up a week, 4 weeks a course of treatment.

**Results** In the treatment group patients, metoprolol succinate sustained-release tablets in the treatment 4 weeks before and after treatment, blood pressure and heart rate were compared, there was a significant difference ( $p < 0.05$ ); in the control group patients before and after treatment, the blood pressure and heart rate were compared, the difference was statistically significant ( $p < 0.05$ ); the treatment group and control group before and after the changes in heart rate were compared, the former was better than the latter, the difference was statistically significant ( $p < 0.05$ ).

**Conclusion** The metoprolol succinate sustained-release tablets sustainable stable blood pressure over 24 h, is one of effective drugs to treat essential hypertension.